BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 32522057)

  • 1. Cost-effectiveness analysis of atezolizumab plus nab-paclitaxel for untreated metastatic triple-negative breast cancer.
    Li J; Zhang T; Lu P; Zhao J; Chen L; Jiang J
    Immunotherapy; 2020 Jul; 12(10):705-713. PubMed ID: 32522057
    [No Abstract]   [Full Text] [Related]  

  • 2. First-Line Treatment With Atezolizumab Plus Nab-Paclitaxel for Advanced Triple-Negative Breast Cancer: A Cost-Effectiveness Analysis.
    Weng X; Huang X; Li H; Lin S; Rao X; Guo X; Huang P
    Am J Clin Oncol; 2020 May; 43(5):340-348. PubMed ID: 32028340
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness analysis of atezolizumab in advanced triple-negative breast cancer.
    Phua LC; Lee SC; Ng K; Abdul Aziz MI
    BMC Health Serv Res; 2020 Jun; 20(1):581. PubMed ID: 32580722
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness Analysis of Atezolizumab Plus Nab-Paclitaxel for Advanced PD-L1 Positive Triple-Negative Breast Cancer in Japan.
    Chisaki Y; Kuwada Y; Matsumura C; Yano Y
    Clin Drug Investig; 2021 Apr; 41(4):381-389. PubMed ID: 33674955
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial.
    Schmid P; Rugo HS; Adams S; Schneeweiss A; Barrios CH; Iwata H; Diéras V; Henschel V; Molinero L; Chui SY; Maiya V; Husain A; Winer EP; Loi S; Emens LA;
    Lancet Oncol; 2020 Jan; 21(1):44-59. PubMed ID: 31786121
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atezolizumab Plus Chemotherapy vs. Chemotherapy in Advanced or Metastatic Triple-Negative Breast Cancer: A Cost-Effectiveness Analysis.
    Liu X; Lang Y; Liao Y; Zhu Y
    Front Public Health; 2021; 9():756899. PubMed ID: 34778188
    [No Abstract]   [Full Text] [Related]  

  • 7. Atezolizumab (in Combination with Nab-Paclitaxel): A Review in Advanced Triple-Negative Breast Cancer.
    Kang C; Syed YY
    Drugs; 2020 Apr; 80(6):601-607. PubMed ID: 32248356
    [TBL] [Abstract][Full Text] [Related]  

  • 8. First-line atezolizumab in addition to bevacizumab plus chemotherapy for metastatic, nonsquamous non-small cell lung cancer: A United States-based cost-effectiveness analysis.
    Wan X; Luo X; Tan C; Zeng X; Zhang Y; Peng L
    Cancer; 2019 Oct; 125(20):3526-3534. PubMed ID: 31287562
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer.
    Schmid P; Adams S; Rugo HS; Schneeweiss A; Barrios CH; Iwata H; Diéras V; Hegg R; Im SA; Shaw Wright G; Henschel V; Molinero L; Chui SY; Funke R; Husain A; Winer EP; Loi S; Emens LA;
    N Engl J Med; 2018 Nov; 379(22):2108-2121. PubMed ID: 30345906
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of adding atezolizumab to first-line chemotherapy in patients with advanced triple-negative breast cancer.
    Wu B; Ma F
    Ther Adv Med Oncol; 2020; 12():1758835920916000. PubMed ID: 32426048
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of pembrolizumab plus chemotherapy as first-line treatment in PD-L1-positive metastatic triple-negative breast cancer.
    Huang M; Fasching P; Haiderali A; Pan W; Gray E; Zhou ZY; Hu P; Chaudhuri M; Bailly De Tilleghem CL; Cappoen N; O'Shaughnessy J
    Immunotherapy; 2022 Sep; 14(13):1027-1041. PubMed ID: 35796042
    [No Abstract]   [Full Text] [Related]  

  • 12. Subgroup analysis of Japanese patients in a Phase 3 study of atezolizumab in advanced triple-negative breast cancer (IMpassion130).
    Iwata H; Inoue K; Kaneko K; Ito Y; Tsugawa K; Hasegawa A; Nakagawa S; Kuratomi H; Tamura K
    Jpn J Clin Oncol; 2019 Dec; 49(12):1083-1091. PubMed ID: 31612909
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of atezolizumab plus chemotherapy for advanced non-small-cell lung cancer.
    Lin S; Luo S; Zhong L; Lai S; Zeng D; Rao X; Huang P; Weng X
    Int J Clin Pharm; 2020 Aug; 42(4):1175-1183. PubMed ID: 32524512
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-Effectiveness Analysis of Atezolizumab Plus Chemotherapy in the First-Line Treatment of Metastatic Non-Squamous Non-Small Cell Lung Cancer.
    Ding D; Hu H; Liao M; Shi Y; She L; Yao L; Zhu Y; Zeng S; Huang J
    Adv Ther; 2020 May; 37(5):2116-2126. PubMed ID: 32193809
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Economic Evaluation of Cisplatin Plus Gemcitabine Versus Paclitaxel Plus Gemcitabine for the Treatment of First-Line Advanced Metastatic Triple-Negative Breast Cancer in China: Using Markov Model and Partitioned Survival Model.
    Rui M; Shi F; Shang Y; Meng R; Li H
    Adv Ther; 2020 Sep; 37(9):3761-3774. PubMed ID: 32647912
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial.
    Mittendorf EA; Zhang H; Barrios CH; Saji S; Jung KH; Hegg R; Koehler A; Sohn J; Iwata H; Telli ML; Ferrario C; Punie K; Penault-Llorca F; Patel S; Duc AN; Liste-Hermoso M; Maiya V; Molinero L; Chui SY; Harbeck N
    Lancet; 2020 Oct; 396(10257):1090-1100. PubMed ID: 32966830
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of Atezolizumab Combination Therapy for First-Line Treatment of Metastatic Nonsquamous Non-Small Cell Lung Cancer in the United States.
    Criss SD; Mooradian MJ; Watson TR; Gainor JF; Reynolds KL; Kong CY
    JAMA Netw Open; 2019 Sep; 2(9):e1911952. PubMed ID: 31553470
    [TBL] [Abstract][Full Text] [Related]  

  • 18. First-line atezolizumab plus chemotherapy in advanced non-squamous non-small cell lung cancer: a cost-effectiveness analysis from China.
    Yang Z; Zhu Y; Xiang G; Hua T; Ni J; Zhao J; Lu Y; Wu Y; Chang F
    Expert Rev Pharmacoecon Outcomes Res; 2021 Oct; 21(5):1061-1067. PubMed ID: 33682554
    [No Abstract]   [Full Text] [Related]  

  • 19. The cost-effectiveness of atezolizumab in first-line for metastatic triple negative breast cancer is heavily linked to PD-L1 level.
    Giuliani J; Mantoan B; Bonetti A
    J Oncol Pharm Pract; 2021 Jul; 27(5):1245-1247. PubMed ID: 34018861
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-Effectiveness of Atezolizumab Plus Chemotherapy as First-Line Therapy for Metastatic Urothelial Cancer.
    Qin S; Yi L; Li S; Tan C; Zeng X; Wang L; Peng Y; Wan X
    Adv Ther; 2021 Jun; 38(6):3399-3408. PubMed ID: 34019245
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.